Secukinumab

• Target:

  IL Receptor|||Interleukin

• Related Pathways:

  Immunology/Inflammation

• Purity:

  0.991

• Bioactivity:

  Secukinumab is a fully humanized monoclonal anti-IL-17A antibody and the first in its class to be approved by the US Food and Drug Administration for the treatment of moderate to severe plaque psoriasis.

• Shipping Conditions:

  Cool pack

• Storage Temperature:

  -20°C

• CAS Number:

  1229022-83-6